0001193125-23-285182.txt : 20231129 0001193125-23-285182.hdr.sgml : 20231129 20231129161526 ACCESSION NUMBER: 0001193125-23-285182 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231129 FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mereo Biopharma Group plc CENTRAL INDEX KEY: 0001719714 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38452 FILM NUMBER: 231452398 BUSINESS ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF BUSINESS PHONE: 4403330237300 MAIL ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF 6-K 1 d525946d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2023

Commission File Number: 001-38452

 

 

MEREO BIOPHARMA GROUP PLC

(Translation of registrant’s name into English)

 

 

4th Floor, One Cavendish Place,

London, W1G 0QF, United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 28, 2023, Dr. Denise Scots-Knight, Mereo BioPharma Group plc’s (the “Company”) Chief Executive Officer, purchased 150,000 American Depositary Shares (“ADSs”), each representing five ordinary shares, nominal value £0.003 per share, of the Company in open market transactions at an average price of approximately $1.96 per ADS.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 29, 2023

 

MEREO BIOPHARMA GROUP PLC
By:  

/s/ Charles Sermon

  Name: Charles Sermon
  Title: General Counsel